Immuneering financials
$4.13−0.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$19.0M | -$15.3M | -$13.8M | -$15.4M | -$14.8M | -$15.5M | -$18.6M | -$15.3M | -$14.9M | -$15.3M | -$16.3M | -$13.9M |
| Net income | -$17.3M | -$13.5M | -$11.6M | -$15.0M | -$14.4M | -$15.0M | -$18.1M | -$14.6M | -$14.1M | -$14.3M | -$15.1M | -$12.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.27 | $-0.21 | $-0.18 | $-0.38 | $-0.40 | $-0.42 | $-0.58 | $-0.49 | $-0.47 | $-0.49 | $-0.51 | $-0.43 |
| EBITDA | -$18.9M | -$15.2M | -$13.7M | -$15.3M | -$14.7M | -$15.4M | -$18.5M | -$15.2M | -$14.8M | -$15.2M | -$16.2M | -$13.8M |
| Operating cash flow | -$16.5M | -$18.4M | -$9.8M | -$12.0M | -$9.4M | -$14.1M | -$14.5M | -$13.5M | -$11.5M | -$15.5M | -$11.8M | -$12.0M |
| Free cash flow | -$16.5M | -$18.5M | -$10.0M | -$12.0M | -$9.4M | -$14.1M | -$14.5M | -$13.5M | -$11.6M | -$15.5M | -$11.9M | -$12.1M |
| Diluted shares | 64.7M | 64.7M | 64.9M | 39.7M | 36.0M | 35.5M | 31.1M | 29.8M | 29.7M | 29.4M | 29.3M | 29.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.3M | $47.3M | $128.6M | $227.6M | $26.4M | $35.9M |
| Short-term investments | $108.6M | $109.4M | $44.2M | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $202.1M | $214.8M | $232.0M | $241.1M | $40.1M | $50.7M |
| Total liabilities | $11.3M | $8.3M | $13.5M | $13.1M | $11.1M | $8.8M |
| Shareholders' equity | $190.7M | $206.5M | $218.5M | $228.0M | $28.9M | $41.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology